Compare Prospect Capital Corporation (PSEC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs TransMedics Group Inc — how do they compare? Prospect Capital Corporation trades at $1.8 (market cap $974.22M), while TransMedics Group Inc trades at $80.9 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 2.8× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 23.01% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and TransMedics Group Inc for 24 Days on average.
| PSEC | TMDX | |
|---|---|---|
Market Cap | $974.22M | $2.74B |
Volume | 5,779,996 | 949,331 |
Sector | Financials | Health |
52-Week High | $3.05 | $150.42 |
52-Week Low | $1.82 | $61.99 |
Typical Hold Time | 78 Days | 24 Days |
Enterprise Value | $2.73B | $3.13B |
Dividend Yield | 23.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.84, up 0.55% on the day, with a bearish technical signal from moving averages despite bullish RSI readings. The company reported negative revenue and net income for 2025, though recent quarterly EPS have beaten expectations. Dividend distributions continue, but analyst consensus is mixed with a majority hold rating. Recent news highlights distribution announcements and management commentary on lower middle-market opportunities.
The outlook is cautious; PSEC's high yield and low P/B ratio present value, but persistent negative cash flow, volatile profitability, and a bearish technical trend pose significant risks. Investor sentiment is divided, with concerns over NAV erosion and portfolio contraction offset by income-focused appeal.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
